Allarity Therapeutics, Inc. Common Stock earnings per share and revenue
On 14. Nov. 2025, ALLR reported earnings of -0.19 USD per share (EPS) for Q3 25, beating the estimate of -0.23 USD, resulting in a 19.01% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.84% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.22 USD, with revenue projected to reach -- USD, implying an increase of 15.79% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Allarity Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Allarity Therapeutics, Inc. Common Stock reported EPS of -$0.19, beating estimates by 19.01%, and revenue of $0.00, 0% as expectations.
How did the market react to Allarity Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -0.84%, changed from $1.19 before the earnings release to $1.18 the day after.
When is Allarity Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 31. März 2026.
What are the forecasts for Allarity Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Allarity Therapeutics, Inc. Common Stock is expected to report EPS of -$0.22 and revenue of -- for Q4 2025.